CPT® Code 38212

1. Indications

The procedure associated with CPT® Code 38212 is indicated for patients undergoing hematopoietic progenitor cell transplantation, where the removal of red blood cells from the harvested collection is necessary. This procedure is typically performed in the context of treating various hematological conditions, including but not limited to:

• Bone Marrow Disorders Conditions such as leukemia or lymphoma that necessitate the use of stem cell transplantation.
• Stem Cell Transplantation Patients preparing for autologous or allogeneic stem cell transplants where the purity of the cell collection is critical.
• Cell Collection Preparation Situations where previously harvested hematopoietic progenitor cells need to be processed to ensure optimal outcomes during infusion.

2. Procedure

The procedure for CPT® Code 38212 involves several critical steps to ensure the effective preparation of hematopoietic progenitor cells. Each step is designed to maintain the integrity and viability of the cells while removing unwanted components.

• Step 1: Thawing of Cells The first step involves thawing the previously harvested hematopoietic progenitor cells that have been preserved in a cryoprotectant solution. This is done carefully to prevent damage to the cells, ensuring they remain viable for infusion.
• Step 2: Red Blood Cell Removal Following thawing, the next step is the specific removal of red blood cells from the harvested collection. This is a crucial part of the procedure, as the presence of red blood cells can lead to complications during the infusion process. Various techniques may be employed to achieve this, including centrifugation or filtration methods.
• Step 3: Preparation for Infusion After the red blood cells have been removed, the hematopoietic progenitor cells are prepared for infusion. This may involve resuspending the cells in an appropriate solution to ensure they are in optimal condition for administration to the patient.

3. Post-Procedure

Post-procedure care following the preparation of hematopoietic progenitor cells is essential to monitor the patient's response and ensure the success of the transplantation. Patients may require observation for any adverse reactions to the infusion, and supportive care may be necessary to manage any side effects. Additionally, healthcare providers will typically follow up with the patient to assess the engraftment of the transplanted cells and monitor for any signs of complications or infections. Proper documentation of the procedure and any subsequent care is critical for compliance and reimbursement purposes.